Business
Update on US launch
Update on US launch.
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n Futura Medical plc\n(\"Futura\", \"the Group\" or the \"Company\")\nUpdate on US launch\n \nFutura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that, in its HY 2024 results announcement released this morning, Haleon has confirmed that it expects Eroxon to be available in the US before the end of this year.\n \nThe Company also confirms that trading remains in line with current market expectations for FY2024. Current market expectations do not include any contribution from the US launch in FY2024. As previously announced, the Company plans to give updated guidance on trading at the time of its Interim results in September.\n \nContacts:\n\n\n\n\nFutura Medical plc\n \n \n \n\n\nJames Barder\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n \n\n\nEmma Earl, Will Goode, Mark Rogers (Corporate Finance)\nRupert Dearden (Corporate Broking)\n\n\n+44 (0)20 3100 2000\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nStifel Nicolaus Europe Limited\nJoint Broker\n \n\n\nAlan Selby\nBen Maddison\n \n\n\n+44 (0)207 710 7600\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAlma Strategic Communications\n\n\nRebecca Sanders-Hewett\nSam Modlin\nWill Ellis Hancock\n\n\n+44 (0)20 3405 0205\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to Editors:\nFutura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.\nEroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction (\"ED\"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.\nED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all...